200 related articles for article (PubMed ID: 19734451)
1. E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.
Bandi SR; Brandts C; Rensinghoff M; Grundler R; Tickenbrock L; Köhler G; Duyster J; Berdel WE; Müller-Tidow C; Serve H; Sargin B;
Blood; 2009 Nov; 114(19):4197-208. PubMed ID: 19734451
[TBL] [Abstract][Full Text] [Related]
2. Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Sargin B; Choudhary C; Crosetto N; Schmidt MHH; Grundler R; Rensinghoff M; Thiessen C; Tickenbrock L; Schwäble J; Brandts C; August B; Koschmieder S; Bandi SR; Duyster J; Berdel WE; Müller-Tidow C; Dikic I; Serve H
Blood; 2007 Aug; 110(3):1004-12. PubMed ID: 17446348
[TBL] [Abstract][Full Text] [Related]
3. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
[TBL] [Abstract][Full Text] [Related]
4. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation.
Agarwal S; Kazi JU; Rönnstrand L
J Biol Chem; 2013 Aug; 288(31):22460-8. PubMed ID: 23803604
[TBL] [Abstract][Full Text] [Related]
6. Direct binding of Cbl to Tyr568 and Tyr936 of the stem cell factor receptor/c-Kit is required for ligand-induced ubiquitination, internalization and degradation.
Masson K; Heiss E; Band H; Rönnstrand L
Biochem J; 2006 Oct; 399(1):59-67. PubMed ID: 16780420
[TBL] [Abstract][Full Text] [Related]
7. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
[TBL] [Abstract][Full Text] [Related]
8. Grb2 mediates negative regulation of stem cell factor receptor/c-Kit signaling by recruitment of Cbl.
Sun J; Pedersen M; Bengtsson S; Rönnstrand L
Exp Cell Res; 2007 Nov; 313(18):3935-42. PubMed ID: 17904548
[TBL] [Abstract][Full Text] [Related]
9. Loss of c-Cbl E3 ubiquitin ligase activity enhances the development of myeloid leukemia in FLT3-ITD mutant mice.
Taylor SJ; Thien CB; Dagger SA; Duyvestyn JM; Grove CS; Lee BH; Gilliland DG; Langdon WY
Exp Hematol; 2015 Mar; 43(3):191-206.e1. PubMed ID: 25534201
[TBL] [Abstract][Full Text] [Related]
10. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.
Reindl C; Quentmeier H; Petropoulos K; Greif PA; Benthaus T; Argiropoulos B; Mellert G; Vempati S; Duyster J; Buske C; Bohlander SK; Humphries KR; Hiddemann W; Spiekermann K
Clin Cancer Res; 2009 Apr; 15(7):2238-47. PubMed ID: 19276253
[TBL] [Abstract][Full Text] [Related]
11. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.
Makishima H; Sugimoto Y; Szpurka H; Clemente MJ; Ng KP; Muramatsu H; O'Keefe C; Saunthararajah Y; Maciejewski JP
Leukemia; 2012 Jul; 26(7):1547-54. PubMed ID: 22246246
[TBL] [Abstract][Full Text] [Related]
12. Role of intracellular tyrosines in activating KIT-induced myeloproliferative disease.
Ma P; Mali RS; Martin H; Ramdas B; Sims E; Kapur R
Leukemia; 2012 Jul; 26(7):1499-1506. PubMed ID: 22297723
[TBL] [Abstract][Full Text] [Related]
13. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
[TBL] [Abstract][Full Text] [Related]
14. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.
Nadeau SA; An W; Mohapatra BC; Mushtaq I; Bielecki TA; Luan H; Zutshi N; Ahmad G; Storck MD; Sanada M; Ogawa S; Band V; Band H
J Biol Chem; 2017 Mar; 292(9):3666-3682. PubMed ID: 28082680
[TBL] [Abstract][Full Text] [Related]
15. Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders.
Naramura M; Nadeau S; Mohapatra B; Ahmad G; Mukhopadhyay C; Sattler M; Raja SM; Natarajan A; Band V; Band H
Oncotarget; 2011 Mar; 2(3):245-50. PubMed ID: 21422499
[TBL] [Abstract][Full Text] [Related]
16. The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.
Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Toure AA; Buhrlage S; Liu X; Wang J; Gray N; Stone R; Adamia S; Winer E; Sattler M; Griffin JD
J Cell Mol Med; 2020 Feb; 24(3):2145-2156. PubMed ID: 31943762
[TBL] [Abstract][Full Text] [Related]
17. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.
Rathinam C; Thien CB; Flavell RA; Langdon WY
Cancer Cell; 2010 Oct; 18(4):341-52. PubMed ID: 20951944
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.
Duyvestyn JM; Taylor SJ; Dagger SA; Orandle M; Morse HC; Thien CB; Langdon WY
PLoS One; 2014; 9(4):e94717. PubMed ID: 24718698
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells.
Chaix A; Lopez S; Voisset E; Gros L; Dubreuil P; De Sepulveda P
J Biol Chem; 2011 Feb; 286(8):5956-66. PubMed ID: 21135090
[TBL] [Abstract][Full Text] [Related]
20. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling.
Kazi JU; Vaapil M; Agarwal S; Bracco E; Påhlman S; Rönnstrand L
Cell Signal; 2013 Sep; 25(9):1852-60. PubMed ID: 23707526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
